ACHN Achillion Pharmaceuticals, Inc.

4.27
+0  (0%)
Previous Close 4.27
Open 4.27
Price To book 1.45
Market Cap 583.62M
Shares 136,680,000
Volume 1,338,970
Short Ratio 7.77
Av. Daily Volume 1,716,840

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 interim data released November 2016. Phase 2 planned.
ACH-4471
Paroxysmal nocturnal hemoglobinuria (PNH)
Phase 2b trial initiation announced November 30, 2016.
JNJ-4178 - OMEGA-1
Hepatitis C (HCV)

Latest News

  1. Achillion to Present at the Leerink Partners 6th Annual Global Healthcare Conference
  2. Achillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ACHN-US : February 3, 2017
  3. Premarket Biotech Movers: Cytokinetics, Achillion, Qiagen
  4. Coverage initiated on Achillion Pharma by Ladenburg Thalmann
  5. Blog Coverage FDA Approved Orphan Drug Designation for TG Therapeutics' Combination of TG-1101 and TG-1202
  6. Achillion Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ACHN) : January 11, 2017
  7. Achillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ACHN-US : January 10, 2017
  8. Where are the opportunities for investors in health care?
  9. Achillion Receives $15M from J&J for HCV Study Enrolment
  10. ACHILLION PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements an
  11. Achillion Announces Clinical Milestone for the Advancement of JNJ-4178 in Phase 2B Development for Chronic HCV
  12. Achillion Announces Clinical Milestone for the Advancement of JNJ-4178 in Phase 2B Development for Chronic HCV
  13. These 5 Stocks Under $10 Could Make You a Lot of Money
  14. Data Presented at American Society of Hematology Meeting Demonstrate Potential Advantages of Factor D Inhibition for the Treatment of Complement Alternative Pathway-Mediated Diseases
  15. The Main Reason Achillion Pharmaceuticals, Inc. Collapsed 34% in November
  16. Has The Smart Money Found A Winner in Infoblox Inc (BLOX)?
  17. Achillion, J&J to Initiate Phase IIb Study on HCV Combo
  18. Achillion Announces Initiation of Patient Dosing by Janssen in a Global, Short Treatment-Duration Phase 2b Study of JNJ-4178 in Chronic HCV
  19. Achillion Announces Initiation of Patient Dosing by Janssen in a Global, Short Treatment-Duration Phase 2b Study of JNJ-4178 in Chronic HCV
  20. This Metric Says It May Be Time to Buy Achillion Pharmaceuticals, Inc. (ACHN)